All Substitutes


Loading...

Disclaimer

Want to know more?
Read Our Editorial Policy

Did you find this information helpful?

    
PAMORELIN LA 3.75MG INJECTION_1
PAMORELIN LA 3.75MG INJECTION_2
PAMORELIN LA 3.75MG INJECTION_1
20% Off

Pamorelin LA 3.75mg Injection

Prescription Required

Salt Composition : Triptorelin

Manufacturer : DR REDDY'S LABORATORIES LTD

Origin of Medicine : India

MRP: ₹7506
Price : ₹6005
You Save : ₹1501 (20%)

1 Vial(s)

Pincode
Delivery By -

Patient Assistance Programs
Know About PAP

Get financial assistance directly from pharma companies and cover your cost of medicines or get free medicines for eligible patients with patient assistance programs (PAP). We provide proper guidance assistance to patients getting enrolled in the patient assistance program.

Introduction to Pamorelin La 3.75mg Injection

 Pamorelin LA 3.75mg Injection contains an active component as Triptorelin.  It is a medication that belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) analogs. It is primarily used in the field of reproductive medicine for the treatment of various conditions related to hormonal imbalance. One of the most common use is in treating certain hormone-dependent conditions such as prostate cancer, breast cancer, and endometriosis. In prostate cancer, for example, this medication is used to lower the levels of testosterone, which can help slow down the growth of cancer cells.

Pamorelin LA 3.75mg Injection should not be used in individuals who have a known hypersensitivity or allergic reaction to the medication or any of its components. The safety and effectiveness of this medication have not been established in children, so a healthcare professional will carefully consider and monitor its use in this population. Pamorelin LA 3.75mg Injection may have cardiovascular effects, including an increased risk of heart attack or stroke. It should be used cautiously in individuals with a history of cardiovascular disease or those at increased risk.


Uses of Pamorelin La 3.75mg Injection

Pamorelin LA 3.75mg Injection is used to treat the following:

  • Prostate cancer in men
  • Early onset puberty in children 2 years of age and older (precocious puberty)

Therapeutic Effects of Pamorelin La 3.75mg Injection

Pamorelin LA 3.75mg Injection exerts its therapeutic effect by suppressing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through its action on the pituitary gland. This suppression leads to a decrease in the production of sex hormones, such as testosterone and estrogen. By reducing the levels of these hormones, This medication is beneficial in treating hormone-dependent conditions such as prostate cancer, breast cancer, and endometriosis. 


Interaction of Pamorelin La 3.75mg Injection with other drugs

Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Pamorelin LA 3.75mg Injection, reducing effectiveness by causing undesirable side effects.


More Information about Pamorelin La 3.75mg Injection

  • Store at room temperature, between 20°C to 25°C (68°F to 77°F).
  • Keep away from moisture, heat, and light.
  • It should not be frozen.
  • Keep away from children and pets.

How to consume Pamorelin La 3.75mg Injection

Pamorelin LA 3.75mg Injection is typically administered via injection, either subcutaneously (under the skin) or intramuscularly (into the muscle). The specific dosing and frequency of administration will depend on the individual's condition being treated and their response to the medication. It is important to follow the healthcare professional's instructions regarding the administration technique and schedule.


Safety Advices for Pamorelin La 3.75mg Injection

Image Not Available  

Pregnancy

  

Pamorelin LA 3.75mg Injection is generally not recommended for use during pregnancy. If pregnancy is planned or suspected while using this medication, it is important to inform the healthcare professional promptly. They can provide appropriate guidance and make necessary adjustments to the treatment plan. 

Image Not Available  

Breast Feeding

  

The safety of Pamorelin LA 3.75mg Injection during breastfeeding is not well established. It is advisable to avoid using it while breastfeeding unless the potential benefits outweigh the potential risks to the nursing infant.

Image Not Available  

Lungs

  

Pamorelin LA 3.75mg Injection is generally considered safe for use in individuals with lung conditions. However, as with any medication, it is important to consult with a healthcare professional before starting this medication if you have a lung condition or any respiratory issues.

Image Not Available  

Liver

  

Pamorelin LA 3.75mg Injection should be used with caution in individuals with liver impairment or liver disease. The metabolism and elimination of this medication may be affected in such cases. However, there is limited information available specifically regarding the safety in patients with liver conditions.

Image Not Available  

Alcohol

  

The use of Pamorelin LA 3.75mg Injection in combination with alcohol is not well studied, and there is limited information available specifically regarding the interaction between this medication and alcohol. Therefore, it is generally recommended to exercise caution and avoid excessive alcohol consumption while using it.

Image Not Available  

Driving

  

Common side effects of Pamorelin LA 3.75mg Injection may include hot flashes, mood changes, and fatigue. If any of these side effects occur and significantly impact your alertness, concentration, or motor skills, it is advisable to avoid driving or operating machinery until you feel capable of doing so safely.


Side Effects of Pamorelin La 3.75mg Injection

Pamorelin LA 3.75mg Injection cause some side effects like all medications, although not everyone will experience them. 

Serious:

  • Swallowing or breathing trouble
  • Increased lymphocyte count in the blood
  • Swelling of lips, tongue or throat

Common:

  • Hot flushes
  • Weakness
  • Excessive sweating
  • Back pain
  • Impotence
  • Nausea
  • Dry mouth
  • Pain, bruising, redness at the injection site
  • High blood pressure
  • Weight gain
  • Dizziness
  • Headache

Word of Advice

It is important to use of Pamorelin LA 3.75mg Injection with caution and adhere to the following precautions to ensure its safe and effective use. First, always use under the supervision and guidance of a healthcare professional who can monitor your progress and make necessary adjustments to your treatment plan. Inform your healthcare professional about any existing medical conditions, including liver impairment, lung conditions, or pregnancy or breastfeeding, as it may have specific considerations or contraindications in these cases. Adhere to the prescribed dosage and administration instructions, and do not adjust the dose without consulting your healthcare professional.

Be aware of possible side effects, such as hot flashes, mood changes, or fatigue, and promptly report any concerning or persistent symptoms to your healthcare professional. Regular follow-up appointments and monitoring are essential to assess your response to this medication and address any concerns or issues that may arise. By taking these precautions and maintaining open communication with your healthcare professional, you can maximize the benefits of this medication while minimizing potential risks.


FAQs

Q 1. Can Pamorelin LA 3.75mg Injection be used to treat infertility?

Yes, Pamorelin LA 3.75mg Injection can be used in certain cases to treat infertility. It is sometimes prescribed as part of assisted reproductive technologies, such as in vitro fertilization (IVF) or intrauterine insemination (IUI), to regulate the timing of ovulation and enhance the chances of successful fertilization.

Q 2. What is the usual duration of Pamorelin LA 3.75mg Injection treatment?

The duration of Pamorelin LA 3.75mg Injection treatment can vary depending on the specific condition being treated. In some cases, it may be a short-term treatment lasting a few weeks or months, while in other cases, such as in prostate cancer, it may be a long-term treatment lasting several months or years. The duration of treatment is determined by the healthcare professional based on individual factors and treatment goals.

Q 3. Can Pamorelin LA 3.75mg Injection be used in children?

The safety and effectiveness of Pamorelin LA 3.75mg Injection have not been well established in children. Its use in pediatric patients is generally limited and carefully considered on a case-by-case basis. Pediatric patients would require close monitoring and supervision by a healthcare professional familiar with the use in this population.

Q 4. Are there any drug interactions associated with Pamorelin LA 3.75mg Injection?

Pamorelin LA 3.75mg Injection may interact with certain medications, including hormonal therapies and drugs that affect the function of the pituitary gland. It is important to inform your healthcare professional about all the medications you are taking, including prescription, over-the-counter, and herbal products, to minimize the risk of potential interactions.

Q 5. Can Pamorelin LA 3.75mg Injection cause menopause-like symptoms?

Yes, Pamorelin LA 3.75mg Injection can cause menopause-like symptoms such as hot flashes, night sweats, and mood changes. These symptoms occur due to the suppression of sex hormone levels, particularly estrogen, which happens as a result of the Pamorelin LA 3.75mg Injection's mechanism of action. These side effects are usually temporary and may resolve after discontinuing the medication.


Fact Box of Pamorelin La 3.75mg Injection

Molecule name: Triptorelin

Therapeutic class: Hormonal therapy

Pharmacological class: Gonadotropin-releasing hormone (GnRH) analog



 

Indications: 

1. Prostate cancer 

2. Precocious puberty


References

  1. Ipsen Limited, Electronic Medicines Compendium (EMC), [Revised on Jun 2017] [Accessed on 18th July 2023],  https://www.medicines.org.uk/emc/files/pil.5906.pdf
  2. Allergan, US Food & Drug Administration, [Revised on Dec 2018] [Accessed on 18th July 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020715s040,021288s035,022427s015lbl.pdf
  3. Claudine Isaacs, Anton Wellstein, and Anna T. Riegel, Hormones and Related Agents in the Therapy of Cancer, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1237-1247.

Disclaimer

MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.